Breast Cancer Associated Antibodies
The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2006 by Lab Discoveries Ltd..
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
Lab Discoveries Ltd.
Information provided by:
Lab Discoveries Ltd.
ClinicalTrials.gov Identifier:
NCT00331942
First received: May 27, 2006
Last updated: March 1, 2007
Last verified: April 2006
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To determine the ability of the Cimmunology process to lead to in vitro antibody production, the ability of the ELISA assays to detect any of those antibodies, and to establish the relationship between the ELISA results and the clinical / pathological status of the patient. The statistical significance of the CAAb test results will be determined.
| Condition |
|---|
|
Breast Cancer |
| Study Type: | Observational |
| Study Design: | Observational Model: Defined Population Primary Purpose: Screening Time Perspective: Cross-Sectional Time Perspective: Retrospective/Prospective |
| Official Title: | Study of Breast Cancer Associated Antibodies |
Resource links provided by NLM:
Further study details as provided by Lab Discoveries Ltd.:
| Estimated Enrollment: | 100 |
| Study Start Date: | July 2006 |
| Estimated Study Completion Date: | May 2008 |
Show Detailed Description Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria BC:
- Subjects 18 years or over.
- Patients diagnosed with suspected breast cancer, (positive mammography or ultrasound or physical examination) and have a positive biopsy.
- Patients willing to participate as evidenced by signing the written informed consent.
Exclusion Criteria BC:
- Subjects less than 18 years
- Patients with prior history of other tumors (except skin cancer)
- Hematologic systemic disorders
- Patients that have undergone chemotherapy
- Patients that have been under anesthesia in the last three months.
- Patient not willing to sign written informed consent.
Inclusion Criteria Control -
- Subjects 18 years or over
- Patients willing to participate as evidenced by signing the written informed consent
- Subjects had a negative mammography in the past three months.
Exclusion Criteria Control -
- Subjects less than 18 years
- Hematological malignancies
- History of any past tumors
- Other breast pathology
- Patients that have been under anesthesia in the last three months
- Patients treated with immuno-suppressant drugs
- Patient not willing to sign written informed consent
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00331942
Contacts
| Contact: Alon Hayka | +972 544 631237 | alonhayka@yahoo.com |
Locations
| Israel | |
| Soroka | Recruiting |
| Beer-Sheva, Israel | |
| Contact: Michal Koretz, Dr. 972 8 6403336 | |
| Carmel Medical center | Recruiting |
| Haifa, Israel | |
| Contact: Pnina Engelman, Dr. 972 4 8787909 | |
Sponsors and Collaborators
Lab Discoveries Ltd.
Investigators
| Principal Investigator: | Tamar J Cohen, Phd. | Lab Discoveries |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00331942 History of Changes |
| Other Study ID Numbers: | LD-BC-CAAb |
| Study First Received: | May 27, 2006 |
| Last Updated: | March 1, 2007 |
| Health Authority: | Israel: Ministry of Health |
Keywords provided by Lab Discoveries Ltd.:
|
Breast Cancer Associated Antibodies |
Additional relevant MeSH terms:
|
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases |
Antibodies Immunoglobulins Immunologic Factors Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 19, 2013